Elanco Animal Health Incorporated Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Elanco Animal Health Incorporated (ELAN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 1.60 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- Elanco Animal Health Incorporated antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 1.60M shares, a 56.76% decline year-over-year.
- Elanco Animal Health Incorporated antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 1.50M shares, a 59.46% decline year-over-year.
- Elanco Animal Health Incorporated antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 8.10M shares, a 800.00% increase year-over-year.
- Elanco Animal Health Incorporated antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 3.70M shares, a 5.71% increase year-over-year.
- Elanco Animal Health Incorporated antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 7.50M shares, a 435.71% increase from fiscal 2024.
- Elanco Animal Health Incorporated antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 1.40M shares, a 51.72% decline from fiscal 2023.
- Elanco Animal Health Incorporated antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 2.90M shares, a 12.12% decline from fiscal 2022.
- Elanco Animal Health Incorporated antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 3.30M shares, a 3.13% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 1.60M shares 10-Q · filed 2026-08-05 | 1.30M shares 10-Q · filed 2026-08-05 | ||||||
| 2026-03-31 | 1.50M shares 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | 7.50M shares 10-K · filed 2026-02-24 | |||||||
| 2025-09-30 | 8.10M shares 10-Q · filed 2025-11-05 | 2.40M shares 10-Q · filed 2025-11-05 | ||||||
| 2025-06-30 | 3.70M shares 10-Q · filed 2026-08-05 | 3.30M shares 10-Q · filed 2026-08-05 | ||||||
| 2025-03-31 | 3.70M shares 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | 1.40M shares 10-K · filed 2026-02-24 | |||||||
| 2024-09-30 | 900.00K shares 10-Q · filed 2025-11-05 | 700.00K shares 10-Q · filed 2025-11-05 | ||||||
| 2024-06-30 | 3.50M shares 10-Q · filed 2025-08-07 | 3.50M shares 10-Q · filed 2025-08-07 | ||||||
| 2024-03-31 | 800.00K shares 10-Q · filed 2025-05-07 | |||||||
| 2023-12-31 | 2.90M shares 10-K · filed 2026-02-24 | |||||||
| 2023-09-30 | 2.70M shares 10-Q · filed 2024-11-07 | 2.70M shares 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | 2.00M shares 10-Q · filed 2024-08-08 | 1.80M shares 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | 1.40M shares 10-Q · filed 2024-05-08 | |||||||
| 2022-12-31 | 3.30M shares 10-K · filed 2025-02-25 | |||||||
| 2022-09-30 | 4.40M shares 10-Q · filed 2023-11-07 | 2.60M shares 10-Q · filed 2023-11-07 | ||||||
| 2022-06-30 | 3.20M shares 10-Q · filed 2023-08-07 | 1.60M shares 10-Q · filed 2023-08-07 | ||||||
| 2022-03-31 | 100.00K shares 10-Q · filed 2023-05-09 | |||||||
| 2021-12-31 | 3.20M shares 10-K · filed 2024-02-26 | 1.80M shares 10-K · filed 2022-02-28 | ||||||
| 2021-09-30 | 3.70M shares 10-Q · filed 2022-11-08 | 1.70M shares 10-Q · filed 2021-11-05 | 3.90M shares 10-Q · filed 2022-11-08 | 1.60M shares 10-Q · filed 2021-11-05 | ||||
| 2021-06-30 | 4.20M shares 10-Q · filed 2022-08-08 | 1.40M shares 10-Q · filed 2021-08-09 | 4.30M shares 10-Q · filed 2022-08-08 | 1.50M shares 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | 4.40M shares 10-Q · filed 2022-05-09 | 1.60M shares 10-Q · filed 2021-05-07 | ||||||
| 2020-12-31 | 4.10M shares 10-K · filed 2023-03-01 | 2.10M shares 10-K · filed 2022-02-28 | ||||||
| 2020-09-30 | 1.60M shares 10-Q · filed 2021-11-05 | 1.90M shares 10-Q · filed 2021-11-05 | ||||||
| 2020-06-30 | 2.30M shares 10-Q · filed 2021-08-09 | 2.10M shares 10-Q · filed 2021-08-09 | ||||||
| 2020-03-31 | 1.80M shares 10-Q · filed 2021-05-07 | |||||||
| 2019-12-31 | 100.00K shares 10-K · filed 2022-02-28 | |||||||
| 2019-09-30 | 100.00K shares 10-Q · filed 2020-11-06 | 100.00K shares 10-Q · filed 2020-11-06 | ||||||
| 2019-06-30 | 100.00K shares 10-Q · filed 2020-07-30 | 100.00K shares 10-Q · filed 2020-07-30 | ||||||
| 2019-03-31 | 200.00K shares 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |